Globalpharma exhibits new generics brands at DUPHAT 2013
- United Arab Emirates: Tuesday, March 12 - 2013 at 09:11
- PRESS RELEASE
Committed to strengthening the pharmaceutical sector in the UAE, Globalpharma, pharmaceutical company in the UAE and a subsidiary of Dubai Investments PJSC, is exhibiting its wide selection of branded generics medicines at the Dubai International Pharmaceuticals and Technologies conference and exhibition (DUPHAT) 2013.
Globalpharma is using the opportunity to showcase its branded-generics that are manufactured in accordance with international quality, safety and production standards.
Branded-generics are drugs that are scientifically formulated using the same core chemical ingredients found in the original medicine that is off-patent.
The company's unique generics line-up includes Gloclav, Atorlip, Emifenac DT, Emilok, as well as recently launched products such as Emivanz and Emipride.
Jamil Akhtar, General Manager, Globalpharma, said, "The local health ministry is continuously promoting the need to develop the generics sector in the UAE, in order to ensure the timely availability of medication at affordable prices. Globalpharma is conscious of the demand, and has gradually increased its offering of generics through a well-developed infrastructure and long-standing local market expertise."
"DUPHAT is a key event that highlights the progress of the regional pharma industry, and addresses the concerns and needs of local pharmaceutical manufacturers. The event has given Globalpharma a chance to explore new opportunities and forge synergies with international pharmaceutical companies looking to enter the Middle East market. We congratulate the organisers and the DHA on yet another successful edition of the conference, and look forward to continued collaboration as part of our growth strategy," he added.
Globalpharma manufactures and markets pharmaceutical products in more than 20 countries across the Middle East, Africa and Far East. The company produces a diverse range of medicines including antibiotics, analgesics/NSAIDs, anti-ulcerant, respiratory products, nutritional supplements, as well medication for chronic conditions such as cardiovascular disease and diabetes.
Globalpharma started its commercial operation in 2003 and within a short span of time emerged as a quality-centric and reliable player in the MEA pharmaceutical market.
Articles in this section are primarily provided directly by the companies appearing or PR agencies which are solely responsible for the content. The companies concerned may use the above content on their respective web sites provided they link back to http://www.ameinfo.com
Any opinions, advice, statements, offers or other information expressed in this section of the AMEinfo.com Web site are those of the authors and do not necessarily reflect the views of Mediaquest FZ LLC. Mediaquest FZ LLC is not responsible or liable for the content, accuracy or reliability of any material, advice, opinion or statement in this section of the AMEinfo.com Web site.